Share:
DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena s clinical pipeline. Hideki brings valuable experience and expertise to our team as we look ahead towards transitioning to a fully integrated research, development and commercial biotechnology company, said Gene Kinney, PhD, President and Chief Executive Officer. His experience leading several late-stage development programs in neurology and rare disease indications through registration and launch is particularly relevant as we advance our pipeline of programs in these areas. We are delighted to welcome him to the team as we prepare for our next
Investegate |Prothena Corporation plc Announcements | Prothena Corporation plc: Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021 investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
(2)
Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer s disease
New pre-specified exploratory subgroup analyses and new digital biomarker data from Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson s disease
will be featured in two separate presentations
DUBLIN, Ireland, Feb. 24, 2021 (GLOBE NEWSWIRE) Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced three oral presentations and participation in a live forum at The 15
th International Conference on Alzheimer s and Parkinson s Diseases (AD/PD 2021). Prothena will present new preclinical data demonstrating that targeting a novel epitope with PRX005, an anti-tau antibody, resulted in superior attributes for the potential treatment of Alzheimer
Prothena Corporation plc: Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
VITAL study 9-month results expected to be presented at medical conference in 2021
Prasinezumab
New pre-specified exploratory subgroup analyses from Part 1 of the Phase 2 PASADENA study to be presented at the 15th International Conference for Alzheimer s and Parkinson s Diseases in March 2021 (ADPD 2021)
$60 million clinical milestone payment to be achieved upon first patient dosed in late-stage Phase 2b study in patients with early Parkinson s disease; further details expected in 2Q 2021
Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference